Roche FY Revenues: $34.5 billion (+17%)* FY Earnings: $7.3 billion (+34%)* Comments: Pharmaceutical sales were up 21% to $27.3 billion driven primarily by key oncology products: MabThera/Rituxan, Herceptin, Avastin, and Xeloda; the flu medicine Tamiflu, Genentech’s ophthalmology drug Lucentis, and the osteoporosis medicine Bonviva/Boniva. The company received marketing approvals for Avastin in lung cancer, Herceptin in early-stage breast cancer and MabThera/Rituxan in rheumatoid ...